A comparison of therapeutic effects of teicoplanin versus vancomycin in patients admitted to the Intensive Care Unit after cardiac surgery

A comparison of therapeutic effects of teicoplanin versus vancomycin in patients admitted to the Intensive Care Unit after cardiac surgery because of MRSA infectious endocarditis in Masih Daneshvari hospital between years 2012-2016

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016022220592N4

Enrollment

Registered

2016-06-21

Start date

2012-08-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocarditis. Acute endocarditis, unspecified

Interventions

Intervention 1: Intenvention : Teicoplanin, Teicoplanin was used by intravenous and intramuscular injection and single dose daily. Intervention 2: Control: Vancomycin, Initial Vancomycin dose was 150

Treatment - Drugs

Intenvention : Teicoplanin, Teicoplanin was used by intravenous and intramuscular injection and single dose daily.

Control: Vancomycin, Initial Vancomycin dose was 1500 mg every 12 hours until serum concentration monitoring indicates the need for higher dosing.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Exclusion criteria: Prohibition of use for each of the two drugs Inclusion Criteria: Surgery complications in invective endocarditis caused by organisms

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Culture and isolation. Timepoint: at the start of the study and after 2 months. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad reza Hashemian

Masih Daneshvari Hospital

smrhashemian@sbmu.ac.ir+98 21 2610 9512

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026